Diffuse Mixed Small and Large Cell Lymphoma

Diffuse mixed lymphomas are NCI classified aggressive lymphomas which comprise 6 to 7% of all non-Hodgkin's lymphoma, with a median age of 58 and a range of about 20-70 years of age. Extranodal involvement (outside of lymph nodes) is seen in 60% of cases, including the bone marrow in 14%.

Web Resources:

• NCI Non-Hodgkin's Lymphoma Information

• Information from Hematopathology

• Details from Frontiers in Bioscience

 

 

Resources

The Hematopathology of Lymphoma - technical but full of very good information.

Frontiers in Bioscience is a source of B-cell information.

eMedicine Abstract

 

Related Articles

Non-Hodgkin's Lymphoma Information Pages:

Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma: Diagnosis

Non-Hodgkin's Lymphoma: Aggressive Lymphomas

Non-Hodgkin's Lymphoma: Indolent Lymphomas

Non-Hodgkin's Lymphoma: Treatment

Non-Hodgkin's Lymphoma: Resources

Bone Marrow and Stem Cell Transplants

Other Pages of Interest:

Childhood Non-Hodgkin's Lymphoma Information Pages

The Lymphoma Information Network

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap